Posted on Mar 08, 2022
International Women’s Day is a time to celebrate the social, economic, cultural and political achievements of women everywhere. This year, the focus is on how to #breakthebias that women see in many aspects of their lives.
As an organisation focused on women’s health, we are very aware of the issues many women face when it comes to diagnosis and treatment for certain conditions. At Cerca Biotech we specifically focus on two of these, Breast Cancer and Pre-Eclampsia.
Decades-old procedures deemed ‘good enough’ for the detection and diagnosis of Breast Cancer and Pre-Eclampsia can and should be better. Women deserve diagnostic testing that is faster, more accessible and economical than it has been in the past.
That’s where we can help. 1 in 7 women will be diagnosed with Breast Cancer during their lifetime. Pre-Eclampsia affects approximately 4.6% of pregnancies globally. Both of these conditions depend on accessible, rapid testing to improve potential outcomes.
MammaTyper® and Pre-eclampsia Vue™ are cutting-edge, easily distributable and economical diagnostic tests that can be carried out in a wide variety of clinical settings.